...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
...instance - benefits patients, as long as the researcher has no financial stake in the product and is not paid to speak about the drug to other doctors, like a traveling pitchman. Others say industry and academic researchers are now so deeply intertwined that exposing doctors' private arrangements only stokes suspicion without correcting the real problem: bias. "Having everyone stand up ...
